The recent QuANTUM-R trial aimed to compare quizartinib monotherapy with investigator’s choice such as low dose cytarabine, MEC, or a FLAG-Ida regimen in R/R AML patients with FLT3-ITD mutation [63]. This evidence concerns the gene FLT3 and acute myeloid leukemia.